Fair Value, page-20

The current competitors is the own APS manual assessments in Australia and the other manual assessment used globally since the technology isn't totally objective and 5 out of the 6 manual assessments are required. The grant occurred when there was a Royal Commission into Age Care and the government only extended the grant for 6 months due to COVID-19 and the uptake hasn't been just "slow". It has been non existence globally and stalled in Australia even with the initial government grant and don't use an excuse this was due to the pandemic as you are well aware the government grant and commercialisation globally occurred well before the pandemic. I w9uld be very surprise if there is a T/O from a big pharma or tech company for this limited technology, it's nothing like ResAppDx.